SCHEMBL3910120

SCHEMBL3910120

CCOC(=O)c1cccc(N(C)C(=O)c2cc(-c3ccc(F)cc3)oc2C)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.42
▸ LMNA P02545 4/20 0.42
▸ TP53 P04637 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ TNKS O95271 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3905527 0.87 MAPT (0.41) MAPTLMNATP53HPGDPOLB
SCHEMBL3906995 0.85 RAB9A (0.46) MAPTLMNATP53TNKSKDM4E
SCHEMBL3904664 0.84 TP53 (0.40) MAPTLMNATP53HPGDPOLB
SCHEMBL3905610 0.81 ALDH1A1 (0.39) MAPTLMNAHPGDKDM4ENPC1
SCHEMBL3902334 0.81 KMT2A (0.62) MAPTLMNAHPGDPOLBNPSR1
SCHEMBL13802182 0.79 KMT2A (0.41) MAPTLMNAHPGDNPC1RAB9A
SCHEMBL29858410 0.79 NPC1 (0.48) MAPTLMNAHPGDTNKSKDM4E
SCHEMBL13791085 0.76 CYP1A2 (0.39) MAPTLMNAHPGDPOLBKDM4E
SCHEMBL3903326 0.71 ALDH1A1 (0.59) MAPTLMNAHPGDPOLBNPC1
SCHEMBL3901597 0.70 RAB9A (0.37) MAPTLMNAHPGDKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553867-B2 Furan or thiophene derivative and medicinal use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-30 — — US disclosed
US-7553867-B2 Furan or thiophene derivative and medicinal use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-30 — — US disclosed
US-20060100261-A1 Furan or thiopene derivative and medicinal use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) 2006-05-11 — — US disclosed
EP-1535915-A1 FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100261-A1 Furan or thiopene derivative and medicinal use thereof TXN2, CYP11B2, CYP11B1 MAPT 4697/4885LMNA 3800/4885TP53 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback